What is the optimal therapy for patients with H5N1 influenza?

PLoS Medicine

Volumn 6, Issue 6, 2009, Pages

  White, Nicholas J ^a   Webster, Robert G ^b   Govorkova, Elena A ^b   Uyeki, Timothy M ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CELECOXIB; MESALAZINE; METHYLPREDNISOLONE; OSELTAMIVIR; PERAMIVIR; PIOGLITAZONE; RIBAVIRIN; RIMANTADINE; T 705; UNCLASSIFIED DRUG; ZANAMIVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AVASCULAR NECROSIS; AVIAN INFLUENZA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INHIBITION; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HYPOXEMIA; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; KIDNEY DYSFUNCTION; LENGTH OF STAY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATIENT CARE; PLEURA EFFUSION; PNEUMOTHORAX; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS REPLICATION; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; PRACTICE GUIDELINES AS TOPIC;

EID: 67650217954     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000091     Document Type: Review

References (62)

1. World Health Organization (2003) Guidelines for WHO guidelines. EIP/GPE/EQC/2003.1. Available: http://www.gradeworkinggroup.org/publications/. Accessed 12 May 2009.
2. Shekelle P, Woolf S, Eccles M, Grimshaw J (1999) Clinical guidelines: Developing guidelines. BMJ 318: 593-596.
3. BBC News (2008 August 8) Flu pandemic "gravest risk to UK". Available: http://news.bbc.co.uk/1/hi/uk-politics/7548593.stm. Accessed 12 May 2009.
4. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
5. Crusat M, de Jong MD (2007) Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir Ther 12: 593-602.
6. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
7. Yen HL, Monto AS, Webster RG, Govorkova EA (2005) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192:665-672.
8. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, et al. (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414-1424.
9. Schünemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, et al. (2007) WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7: 21-31.
10. Schünemann HJ, Hill SR, Kakad M, Vist GE, Bellamy R, et al. (2007) Transparent development of the WHO rapid advice guidelines. PLoS Med 4:e119. doi:10.1371/journal.pmed.0040119.
11. Hayden FG, Treanor JJ, Fritz RS, Hayden FG, Treanor JJ, et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 282:1240-1246.
12. Wattanagoon Y, Stepniewska K, Lindegårdh N, Pukrittayakamee S, Silachamroon U, et al. (2009) Pharmacokinetics of high dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 53: 945-952.
13. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, et al. (2008) Rating quality of evidence and strength of recommendations: Going from evidence to recommendations. BMJ 336: 1049-1051.
14. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, et al. (2008) Rating quality of evidence and strength of recommendations GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
15. Rawlins M (2009) De testimonio: On the evidence for decisions about the use of therapeutic interventions. Lancet 372: 2152-2161.
16. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, et al. (2008) Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eurosurveillance 13: pii: 8026.
17. World Health Organization (2009) Influenza A (H1N1) virus resistance to oseltamivir. Available: http://www.who.int/csr/disease/influenza/h1n1-table/en/ index.html. Accessed 12 May 2009.
18. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350: 1023-1035.
19. Hirsch HH, Kaufmann G, Sendi P, Battegey M (2004) Immune reconstitution in HIV-infected patients. Clin Infect Dis 38: 1159-1166.
20. Kuritzkes DR, Walker BD (2007) HIV-1: Pathogenesis, clinical manifestations, and treatment. In: Knipe DM, Howley PM, eds. Field's virology. 5th edition. Philadelphia: Lippincott Williams and Wilkins. pp 1697-1701.
21. World Health Organization (2007) Continuing progress towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. Available: http://www.who.int/csr/disease/avian-influenza/guidelines/ nomenclature/en/index.html. Accessed 12 May 2009.
22. World Health Organization (2007) Clinical management of human infection with avian influenza A (H5N1) virus. Updated advice 15 August 2007. Available: http://www.who.int/csr/disease/avian-influenza/guidelines/ ClinicalManagement07. pdf. Accessed 12 May 2009.
23. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363-370.
24. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, et al. (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52: 3889-3897.
25. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, et al. (2008) Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 105:8091-8096.
26. Aldridge JR Jr, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, et al. (2009) From the Cover: TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 106: 5306-5311.
27. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 14: 126.
28. Simmons CP, Bernasconi NL, Suguitan AL Jr, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178. doi:10.1371/journal.pmed.0040178.
29. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad SciUS A 105: 5986-5991.
30. Stockman LJ, Bellamy R, Garner P (2006) SARS: Systematic review of treatment effects. PLoS Med 3: e343. doi:10.1371/journal.pmed.0030343.
31. Muller MP, Dresser L, Raboud J, McGeer A, Rea E, et al. (2007) Adverse events associated with high-dose ribavirin: Evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy 27: 494-503.
32. Griffith JF, Antonio GE, Kumta SM, Hui DS, Wong JK, et al. (2005) Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 235: 168-175.
33. Hong N, Du XK (2004) Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 59: 602-608.
34. Muller MP, McGeer A, Straus SE, Hawryluck L, Gold WL (2004) Clinical trials and novel pathogens: Lessons learned from SARS. Emerg Infect Dis 10:389-394.
35. Chan PK (2002) Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 34(Suppl 2): S58-S64.
36. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, et al. (2004) Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363: 617-619.
37. World Health Organization (2009) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available: http://www.who.int/csr/disease/avian-influenza/country/cases-table-2009-05-15/ en/index.html. Accessed 15 May 2009.
38. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M (2007) Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007 Jan 24: CD002744.
39. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D (2006) Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2006 Jul 19: CD001265.
40. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, et al. (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: Systematic review and meta-analyses of randomised controlled trials. BMJ 326: 1235.
41. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, et al. (2009) Seasonal influenza in adults and children - Diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48: 1003-1032.
42. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, et al. (2007) Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 45: 1568-1575.
43. Lee N, Chan PK, Choi KW, Lui G, Wong B, et al. (2007) Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 12:501-508.
44. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, et al. (2008) Factors associated with case fatality of human H5N1 virus infections in Indonesia: A case series. Lancet 372: 744-749.
45. Liem NT, Tung CV, Hien ND, Hien TT, Chau NQ, et al. (2009) Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis, E-pub 2009 May 12.
46. Le MTQ, Wertheim HFL, Nguyen HD, Taylor W, Hoang PVM, et al. (2008) Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 3: e3339. doi:10.1371/journal.pone.0003339.
47. Saad MD, Boynton BR, Earhart KC, Mansour MM, Niman HL, et al. (2007) Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1 [Abstract P909]. Options for the Control of Influenza VI; 17-23 June 2007; Toronto, Ontario, Canada. 228 p.
48. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
49. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: Isolation of drug-resistant H5N1 virus. Nature 437: 1108.
50. Yu H, Gao Z, Feng Z, Shu Y, Xiang N, et al. (2008) Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE 3: e2985. doi:10.1371/journal.pone.0002985.
51. Uyeki TM (2009) Human infection with highly pathogenic avian influenza A (H5N1) virus. Clinical issues. Clinical Infect Dis 49: In press.
52. Sedyaningsih ER, Isfandari S, Setiawaty V, Rifati L, Harun S, et al. (2007) Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis 196: 522-527.
53. Kitphati R, Apisarnthanarak A, Chittaganpitch M, Tawatsupha P, Auwanit W, et al. (2008) A nationally coordinated laboratory system for human avian influenza A (H5N1) in Thailand: Program design, analysis, and evaluation. Clin Infect Dis 46: 1394-1400.
54. [No authors listed] (2006) Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec 81: 249-257.
55. Gu J, Xie Z, Gao Z, Liu J, Korteweg C, et al. (2007) H5N1 infection of the respiratory tract and beyond: A molecular pathology study. Lancet 370:1137-1145.
56. Taylor WRJ, Thinh BN, Anh GT, Horby P, Wertheim H, et al. (2008) Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS ONE 3: e3410. doi:10.1371/journal. pone.0003410.
57. Zhou B, Zhong N, Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357: 1450-1451.
58. Wang H, Feng Z, Shu Y, Yu H, Zhou L, et al. (2008) Probable limited personto-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371: 1427-1434.
59. World Health Organization (2008) Infection control recommendations for avian influenza in health-care facilities. Aide-Memoire. Available: http://www.who.int/csr/disease/avian-influenza/guidelines/EPR-AM1-E5.pdf. Accessed 12 May 2009.
60. World Health Organization (2008) Early recognition, reporting and infection control management acute respiratory diseases of potential international concern. Aide-Memoire. Available: http://www.who.int/csr/disease/ avian-influenza/guidelines/EPR-AM4-E3.pdf. Accessed 12 May 2009.
61. Centers for Disease Control and Prevention (2004) Interim recommendations for infection control in health-care facilities caring for patients with known or suspected avian influenza. Available: http://www.cdc.gov/flu/avian/ professional/pdf/infectcontrol.pdf. Accessed 12 May 2009.
62. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. Engl J Med, E-pub 2009 May 7. doi:10.1056/NEJMoa0903810.